News

Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.

 

vial of Immunocidin

ISU College of Veterinary Medicine to Conduct a Study with Immunocidin® in the Treatment of Canine Hemangiosarcoma

NovaVive's anticancer immunotherapeutic for dogs will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in the treatment of splenic hemangiosarcoma (in combination with chemo).

Dr. Jeannette Kelly with dog and sign that reads last chemo treatment

Immunocidin® Demonstrates an Acceptable Safety Profile Following Intravenous Administration in Dogs and Cats with Various Malignancies

Dr. Jeannette Kelly, veterinary oncologist with Veterinary Cancer Care, presented data from a study of multiple IV administrations of Immunocidin® in dogs and cats with various malignancies at the ACVIM Forum last week.

dog running in the grass

NovaVive Inc. Summarizes Canine Cancer Data Presented at World Veterinary Cancer Congress

The results of clinical studies using MCW formulations in ameliorating neutropenia and inducing serum cytokine synthesis were presented at the 3rd World Veterinary Cancer Congress (WVCC) in May, 2016 in Brazil.

Sign up to stay up-to-date with NovaVive news.